British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma. Gut 2023 Dec 07;73(1):16-46
Date
09/29/2023Pubmed ID
37770126Pubmed Central ID
PMC10715509DOI
10.1136/gutjnl-2023-330029Scopus ID
2-s2.0-85173470567 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
These guidelines for the diagnosis and management of cholangiocarcinoma (CCA) were commissioned by the British Society of Gastroenterology liver section. The guideline writing committee included a multidisciplinary team of experts from various specialties involved in the management of CCA, as well as patient/public representatives from AMMF (the Cholangiocarcinoma Charity) and PSC Support. Quality of evidence is presented using the Appraisal of Guidelines for Research and Evaluation (AGREE II) format. The recommendations arising are to be used as guidance rather than as a strict protocol-based reference, as the management of patients with CCA is often complex and always requires individual patient-centred considerations.
Author List
Rushbrook SM, Kendall TJ, Zen Y, Albazaz R, Manoharan P, Pereira SP, Sturgess R, Davidson BR, Malik HZ, Manas D, Heaton N, Prasad KR, Bridgewater J, Valle JW, Goody R, Hawkins M, Prentice W, Morement H, Walmsley M, Khan SAAuthor
Kondragunta Rajendra Prasad MBBS Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Bile Duct NeoplasmsBile Ducts, Intrahepatic
Cholangiocarcinoma
Gastroenterology
Humans